Table 1.
Patient characteristics
|
Total (n = 97) |
High TDI (n = 53) |
Low TDI (n = 16) |
AC(-) (n = 28) |
P value |
P value (high vs. low) |
|
|---|---|---|---|---|---|---|
| Sex (male/female) | 62/35 | 32/21 | 8/8 | 22/6 | 0.122 | 0.468 |
| Age, years | 71 (50–92) | 70 (50–85) | 68.5 (54–79) | 77.5 (59–92) | < 0.001 | 0.863 |
| Preoperative CEA | 2.6 (0.6–45.2) | 2.4 (0.6–45.2) | 4.0 (1.5–24.6) | 2.7 (1–30.6) | 0.507 | 0.344 |
| Preoperative CA19-9 | 135 (0.4–4510) | 108.4 (0.7–4510) | 85.0 (0.4–1511) | 198 (20–2650) | 0.955 | 0.891 |
| Operative method | 0.133a | 0.044a | ||||
| -PD | 64 | 32 | 14 | 18 | ||
| -DP | 28 | 19 | 1 | 8 | ||
| -TP | 5 | 2 | 1 | 2 | ||
| Pathological diagnosis (IDC/inv. IPMC) | 68/29 | 38/15 | 13/3 | 17/11 | 0.179 | 0.163 |
| Pathological T factor (1/2/3/4) | 12/67/12/6 | 7/35/8/3 | 1/12/1/2 | 4/20/3/1 | 0.324 | 0.586 |
| ly (0/1/2/3) | 12/64/12/9 | 7/39/5/2 | 0/9/3/4 | 5/16/4/3 | 0.204 | 0.164 |
| v (0/1/2/3) | 9/31/43/14 | 1/14/28/10 | 0/2/10/4 | 8/15/5/0 | 0.665 | 0.586 |
| UICC stage | 0.102b | 0.586b | ||||
| -IA, IB | 2 | 1 | 0 | 1 | ||
| -IIA | 14 | 6 | 1 | 7 | ||
| -IIB | 41 | 25 | 5 | 11 | ||
| -III | 37 | 19 | 10 | 8 | ||
| -IV | 3 | 2 | 0 | 1 | ||
| Pathological lymph node metastasis (positive/negative) | 80/17 | 45/8 | 15/1 | 20/8 | 0.139 | 0.365 |
| Residual tumor (R0/R1) | 86/11 | 48/5 | 13/3 | 25/3 | 0.592 | 0.315 |
| Time to start AC after surgery, days | 53 (24–399) | 48 (27–399) | 78.5 (24–110) | none | 0.436 | 0.436 |
TDI Total dose intensity, PD Pancreatoduodenectomy, DP Distal pancreatectomy, TP Total pancreatectomy, ly Lymphatic permeation, v Blood vessel invasion, AC Adjuvant chemotherapy, IDC Invasive ductal carcinoma, inv. IPMC Invasive intraductal papillary mucinous carcinoma
aPD vs. DP and TP, bStage ≥ IIB vs. < IIB